Bio & Pharma
MDimune signs research agreement with Australian National University
The Korean biotech company and Austrailian lab plan to find out the therapeutic effect of cell-derived vesicles
By Dec 07, 2022 (Gmt+09:00)
1
Min read
Most Read
Deutsche Bank's Korea IB head quits after country head resigns
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Macquarie Korea Asset Management confirms two nominees
Meritz leaves door open for an M&A, to stay shareholder friendly
Korea's Taeyoung to sell local hotel to speed up debt workout
MDimune, a South Korean biotech company, said on Wednesday that it had signed an agreement with the Clear Vision Research (CVR) Lab, a research group within the Australian National University, to jointly research and develop macular degeneration treatments.
MDimune is a company that possesses cell-derived vesicles(CDVs) production technology that can be used as a drug delivery system by extruding cells.
The CVR Lab is a group that intensively studies age-related macular degeneration within the university, and has conducted initial animal experiments to see whether the CDVs provided by MDimune can be used for the treatment of age-related macular degeneration.
With the latest joint research pact, MDimune and the CVR Lab plan to find out the therapeutic effect of CDVs.
MDimune expects this collaboration to facilitate the commercialization of drug delivery systems.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
Korean stock marketSamyang tops Korean ramen makers by market cap, beating Nongshim
May 17, 2024 (Gmt+09:00)
-
Corporate strategyHanwha Ocean to adopt Kyocera founder Inamori’s amoeba management
May 17, 2024 (Gmt+09:00)
Comment 0
LOG IN